MedTrace Logo

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

NCT04150471 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2019-11-04

No results posted yet for this study

Summary

This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic Myeloid Leukemia) who have achieved EMR (\< 10% IS BCR-ABL) at 3 months after first line treatment with dasatinib. Subjects will be allocated to 80mg QD based on EMR (Early Molecular Response) achievement and early safety profile following a standard of care approach.

Conditions

  • Chronic Myelocytic Leukemia

Interventions

OTHER

RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis

Conventional Q-RT-PCR every 3 months

Sponsors & Collaborators

Principal Investigators

  • Sahee Park · Cancer Research Institute, The Catholic University of Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2020-12-30
Completion
2023-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04150471 on ClinicalTrials.gov